Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Selegiline Approved For Parkinson’s In Orally Disintegrating Tablet Form

This article was originally published in The Pink Sheet Daily

  • News
  • Kathleen Michael

Executive Summary

Valeant’s Zelapar clears FDA after two “approvable” letters.

You may also be interested in...



Serono Adds Newron Parkinson's Disease Agent Safinamide With Licensing Deal

Phase III studies are investigating safinamide as an add-on therapy to dopamine agonists in early Parkinson's disease patients.

Serono Adds Newron Parkinson's Disease Agent Safinamide With Licensing Deal

Phase III studies are investigating safinamide as an add-on therapy to dopamine agonists in early Parkinson's disease patients.

Emsam Antidepressant Patch Approved; April Launch Anticipated

Bristol/Somerset’s product avoids MAOI-class dietary restrictions at the lowest dose.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By